Olaratumab Pregnancy and Breastfeeding Warnings
Brand names: Lartruvo
Olaratumab Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk.
US FDA pregnancy category: Not Assigned
Risk Summary: Based on animal data and its mechanism of action, this drug can cause fetal harm.
No animal studies have been conducted with this drug to evaluate its effect on female reproduction and embryofetal development. Animal knockout models link disruption of platelet-derived growth factor receptor alpha (PDGFR-alpha) signaling to adverse effects on embryofetal development. Administration of an anti-murine PDGFR-alpha antibody to pregnant mice during organogenesis at exposures less than at the maximum recommended human dose caused malformations and skeletal variations. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.
Olaratumab Breastfeeding Warnings
Use is not recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: Because of the potential risk for serious adverse reactions in breastfeeding infants from this drug, the manufacturer recommends that women should not breastfeed during therapy and for 3 months following the last dose.
See also
References for pregnancy information
- (2016) "Product Information. Lartruvo (olaratumab)." Lilly, Eli and Company
References for breastfeeding information
- (2016) "Product Information. Lartruvo (olaratumab)." Lilly, Eli and Company
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.